Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection.

Jillian Kallman Price, Lynn H Gerber,Maria Stepanova,Leyla de Avila,Ali A Weinstein,Huong Pham,Fatema Nader,Mariam Afendy,Kathy Terra,Patrick Austin, Wisna'odom Keo,Andrei Racila,James Michael Estep,Suzannah Gerber,Manisha Verma,Pegah Golabi,Brian P Lam,Zobair Younossi

International journal of general medicine（2023）

引用 1|浏览10

暂无评分

摘要

mAb treated participants had reduced symptom burden and consistently reported fewer symptoms than non-mAb at all time points despite less time since acute illness. Both groups reported a statistically significant decrease in symptoms by 6-month visit with no statistically significant differences between them at follow-up.

查看译文

关键词

monoclonal antibodies, patient-reported outcomes, symptom burden, recovery, COVID-19

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要